Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
79.4M
-
Number of holders
-
57
-
Total 13F shares, excl. options
-
19M
-
Shares change
-
+824K
-
Total reported value, excl. options
-
$422M
-
Value change
-
+$18.2M
-
Number of buys
-
33
-
Number of sells
-
-14
-
Price
-
$22.19
Significant Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) as of Q4 2019
60 filings reported holding AKRO - Akero Therapeutics, Inc. - COMMON STOCK as of Q4 2019.
Akero Therapeutics, Inc. - COMMON STOCK (AKRO) has 57 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19M shares
of 79.4M outstanding shares and own 23.94% of the company stock.
Largest 10 shareholders include Apple Tree Partners IV, L.P. (5.42M shares), venBio Partners LLC (3.94M shares), JANUS HENDERSON GROUP PLC (2.41M shares), Redmile Group, LLC (1.16M shares), HILLHOUSE CAPITAL ADVISORS, LTD. (891K shares), Cormorant Asset Management, LP (741K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (540K shares), BlackRock Inc. (540K shares), BOXER CAPITAL, LLC (482K shares), and BVF INC/IL (451K shares).
This table shows the top 57 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.